Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

NCT03900377 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-cell, Diffuse

Interventions

DRUG: SyB L-0501RI

Sponsor

SymBio Pharmaceuticals